US, EU Nods For Gilead's Vemlidy To Enter Saturated Hep B Market
Vemlidy, Gilead Sciences' follow-on to blockbuster hepatitis B product treatment Viread, has this week won approval in the US and been given the green light for approval in Europe – vital steps in Gilead's long term plan to protect its hep B portfolio from generic erosion.
You may also be interested in...
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
Gilead CEO John Milligan, pressured by an analyst, gave a brief rundown of the company's strategic priorities as investors wait for the company to spend its $34bn in cash on revenue-increasing opportunities to offset declining hepatitis C drug sales.
Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024.